CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,858,940 | +84.9% | 63,000 | +84.2% | 0.96% | +122.9% |
| Q1 2023 | $1,546,524 | +11.2% | 34,200 | 0.0% | 0.43% | +0.7% |
| Q4 2022 | $1,390,230 | -37.8% | 34,200 | 0.0% | 0.43% | -40.2% |
| Q3 2022 | $2,235,000 | -93.5% | 34,200 | +1545.8% | 0.72% | +100.8% |
| Q2 2022 | $34,200,000 | +317.5% | 2,078 | -98.1% | 0.36% | -80.4% |
| Q4 2021 | $8,192,000 | +205.6% | 108,200 | +391.8% | 1.82% | +157.4% |
| Q1 2021 | $2,681,000 | -20.4% | 22,000 | 0.0% | 0.71% | -22.9% |
| Q4 2020 | $3,368,000 | +83.2% | 22,000 | 0.0% | 0.92% | +55.1% |
| Q3 2020 | $1,838,000 | +11.3% | 22,000 | 0.0% | 0.59% | +8.0% |
| Q2 2020 | $1,651,000 | +77.5% | 22,000 | 0.0% | 0.55% | +29.5% |
| Q1 2020 | $930,000 | -30.6% | 22,000 | 0.0% | 0.42% | -12.2% |
| Q4 2019 | $1,340,000 | – | 22,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |